WSJ: Private insurers kept $9B in cash from Medicare

Health insurers have been inflating cost estimates for providing prescription-drug benefits to more than 40 million Medicare beneficiaries, allowing them to cash in $9.1 billion in extra payments from taxpayer funds from 2006 to 2015, according to a report from The Wall Street Journal.

Each year, insurers send cost forecasts for providing benefits to Medicare enrollees to the government, but the estimates are rarely correct and often end up as higher revenue for health insurance companies. These payments have “largely been hidden” from public view, according to the WSJ, and are completed by some of the largest private insurers, including CVS Health, UnitedHealth Group and Humana.

The findings come at a time when drug prices and Medicare Part D costs have skyrocketed over the last several years, jumping 49 percent from $62.9 billion in 2010 to $93.8 billion in 2017, according to the WSJ.

When health insurers overestimate their costs, they can keep a chunk of the change at the end of year. However, if the money received from the government is more than 5 percent of the insurer’s original bid, some of it will have to be paid back to Medicare. In 2015, insurers overestimated costs by $2.2 billion and kept about $1 billion.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”